<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Lin C</submitter><funding>Natural Science Foundation of Fujian Province</funding><funding>Fujian Medical University</funding><funding>National Natural Science Foundation of China</funding><funding>Joint Funds for the Innovation of Science and Technology of Fujian Province</funding><pagination>e340-e349</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC8982379</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>27(4)</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>Nasopharyngeal carcinoma is an Epstein-Barr virus (EBV)-associated tumor that is highly common in southern China. Our previous sequencing data demonstrated that the EBV-encoded microRNA BART8-3p was most upregulated in nasopharyngeal carcinoma (NPC) and was closely associated with the metastasis of NPC. However, the values of plasma BART8-3p in NPC patients have not yet been well characterized.&lt;h4>Material and methods&lt;/h4>We quantified plasma BART8-3p expression by quantitative real-time PCR in 205 newly diagnosed NPC patients. Kaplan-Meier analysis was used to compare overall survival (OS), distant metastasis-free survival (DMFS), and locoregional relapse-free survival (LRRFS) between the groups.&lt;h4>Results&lt;/h4>Plasma pretreatment BART8-3p was highly expressed in NPC pa</pubmed_abstract><journal>The oncologist</journal><pubmed_title>Plasma Epstein-Barr Virus MicroRNA BART8-3p as a Diagnostic and Prognostic Biomarker in Nasopharyngeal Carcinoma.</pubmed_title><pmcid>PMC8982379</pmcid><funding_grant_id>2020J05071</funding_grant_id><funding_grant_id>2019Y9037</funding_grant_id><funding_grant_id>81972717</funding_grant_id><funding_grant_id>2019QH1192</funding_grant_id><pubmed_authors>Pan J</pubmed_authors><pubmed_authors>Lin C</pubmed_authors><pubmed_authors>Lin S</pubmed_authors><pubmed_authors>Lu T</pubmed_authors><pubmed_authors>Zong J</pubmed_authors><pubmed_authors>Lin K</pubmed_authors><pubmed_authors>Su Y</pubmed_authors><pubmed_authors>Zhang B</pubmed_authors><pubmed_authors>Guo Q</pubmed_authors><pubmed_authors>Xu Y</pubmed_authors></additional><is_claimable>false</is_claimable><name>Plasma Epstein-Barr Virus MicroRNA BART8-3p as a Diagnostic and Prognostic Biomarker in Nasopharyngeal Carcinoma.</name><description>&lt;h4>Background&lt;/h4>Nasopharyngeal carcinoma is an Epstein-Barr virus (EBV)-associated tumor that is highly common in southern China. Our previous sequencing data demonstrated that the EBV-encoded microRNA BART8-3p was most upregulated in nasopharyngeal carcinoma (NPC) and was closely associated with the metastasis of NPC. However, the values of plasma BART8-3p in NPC patients have not yet been well characterized.&lt;h4>Material and methods&lt;/h4>We quantified plasma BART8-3p expression by quantitative real-time PCR in 205 newly diagnosed NPC patients. Kaplan-Meier analysis was used to compare overall survival (OS), distant metastasis-free survival (DMFS), and locoregional relapse-free survival (LRRFS) between the groups.&lt;h4>Results&lt;/h4>Plasma pretreatment BART8-3p was highly expressed in NPC pa</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Apr</publication><modification>2026-06-18T08:48:45.478Z</modification><creation>2025-04-19T21:48:17.318Z</creation></dates><accession>S-EPMC8982379</accession><cross_references><pubmed>35380720</pubmed><doi>10.1093/oncolo/oyac024</doi></cross_references></HashMap>